drugset / Trial / NCT05392530

A Study of Two Different Test Formulations Compared to the Reference Formulation of Macitentan in Healthy Adult Participants

NCT05392530

Phase 1 Completed 23 enrolled Actelion
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to assess the rate and extent of absorption of a single oral dose of macitentan given as 2 test formulations compared to the reference formulation under fed conditions in healthy adult participants.

Timeline

Start
2022-05-25
Primary completion
2022-08-30
Completion
2022-09-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Macitentan Other / unclassified 75 mg Oral

Indications

No indication recorded.